DK3071595T3 - Humaniseret anti-kallikrein-2-antistof - Google Patents

Humaniseret anti-kallikrein-2-antistof Download PDF

Info

Publication number: DK3071595T3
Authority: DK; Denmark
Prior art keywords: callicine; antibody; humanized anti; humanized
Prior art date: 2013-11-19

Application number

DK14814696.2T

Other languages

English (en)

Inventor

Sven-Erik Strand

Urpo Juhani Lamminmäki

Kjell Sjöström

Pär Oskar Vilhelmsson Timmermand

Amanda Thuy Tran

Original Assignee

Fredax Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-11-19

Filing date

2014-11-19

Publication date

2019-07-01

2013-11-19 Priority claimed from GB1320408.6A external-priority patent/GB2520353A/en

2014-02-05 Priority claimed from GB201401973A external-priority patent/GB201401973D0/en

2014-11-19 Application filed by Fredax Ab filed Critical Fredax Ab

2019-07-01 Application granted granted Critical

2019-07-01 Publication of DK3071595T3 publication Critical patent/DK3071595T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- G01N33/57555—
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cell Biology (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Reproductive Health (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Enzymes And Modification Thereof (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Microbiology (AREA)

DK14814696.2T 2013-11-19 2014-11-19 Humaniseret anti-kallikrein-2-antistof DK3071595T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB1320408.6A GB2520353A (en)	2013-11-19	2013-11-19	Antibody polypeptides and uses thereof
GB201401973A GB201401973D0 (en)	2014-02-05	2014-02-05	Antibody polypeptides and uses thereof
PCT/GB2014/053420 WO2015075445A1 (en)	2013-11-19	2014-11-19	Humanised anti kallikrein-2 antibody

Publications (1)

Publication Number	Publication Date
DK3071595T3 true DK3071595T3 (da)	2019-07-01

Family

ID=52114029

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK14814696.2T DK3071595T3 (da)	2013-11-19	2014-11-19	Humaniseret anti-kallikrein-2-antistof

Country Status (23)

Country	Link
US (3)	US10100125B2 (da)
EP (2)	EP3071595B1 (da)
JP (4)	JP6599859B2 (da)
KR (3)	KR102574537B1 (da)
CN (2)	CN112898431B (da)
AU (3)	AU2014351611B2 (da)
BR (1)	BR112016011025B1 (da)
CA (1)	CA2930493A1 (da)
CY (1)	CY1121900T1 (da)
DK (1)	DK3071595T3 (da)
ES (1)	ES2728515T3 (da)
HR (1)	HRP20191095T1 (da)
HU (1)	HUE043875T2 (da)
IL (5)	IL311788B1 (da)
LT (1)	LT3071595T (da)
MX (2)	MX383543B (da)
PL (1)	PL3071595T3 (da)
PT (1)	PT3071595T (da)
RS (1)	RS58831B1 (da)
RU (1)	RU2687163C1 (da)
SI (1)	SI3071595T1 (da)
SM (1)	SMT201900338T1 (da)
WO (1)	WO2015075445A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2771037T3 (pl)	2011-10-28	2017-06-30	Fredax Ab	Środki terapeutyczne i ich zastosowania
FI3312749T3 (fi)	2012-03-05	2024-05-31	Oy Arctic Partners Ab	Menetelmiä ja laitteita eturauhassyövän riskin ja eturauhasen tilavuuden ennustamiseen
AU2014351611B2 (en) *	2013-11-19	2020-04-23	Janssen Biotech, Inc.	Humanised anti kallikrein-2 antibody
US12326453B2 (en)	2014-03-28	2025-06-10	Opko Diagnostics, Llc	Compositions and methods for active surveillance of prostate cancer
EP3299977A1 (en)	2014-03-28	2018-03-28	Opko Diagnostics, LLC	Compositions and methods related to diagnosis of prostate cancer
JP6749337B2 (ja)	2015-03-27	2020-09-02	オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニーＯｐｋｏＤｉａｇｎｏｓｔｉｃｓ，Ｌｌｃ	前立腺抗原標準およびその使用
US20180326102A1 (en) *	2015-11-18	2018-11-15	Memorial Sloan Kettering Cancer Center	Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
MA46952A (fr)	2016-12-01	2019-10-09	Regeneron Pharma	Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
IL313695A (en)	2017-02-10	2024-08-01	Regeneron Pharma	Radiolabeled anti-lag3 antibodies for immuno-pet imaging
BR112019020414A2 (pt)	2017-03-30	2020-06-09	Progastrine Et Cancers S.À R.L.	composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina
SG11202000073XA (en)	2017-07-24	2020-02-27	Regeneron Pharma	Anti-cd8 antibodies and uses thereof
BR112021022237A2 (pt)	2019-05-10	2022-03-29	Janssen Biotech Inc	Queladores macrocíclicos e métodos de uso dos mesmos
UY38800A (es) *	2019-07-26	2021-01-29	Janssen Biotech Inc	Receptor de antígeno quimérico (car) anti-hk2
BR112022001368A2 (pt) *	2019-07-26	2022-05-24	Janssen Biotech Inc	Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
PH12022500023A1 (en)	2020-05-27	2024-03-11	Janssen Biotech Inc	Proteins comprising cd3 antigen binding domains and uses thereof
CA3189293A1 (en)	2020-07-17	2022-01-20	Janssen Biotech, Inc.	Anti-idiotypic antibodies against anti-klk2 antibodies
JP2023547703A (ja) *	2020-11-10	2023-11-13	ヤンセンバイオテツク，インコーポレーテツド	大員環化合物及びその使用方法
CN112608365B (zh) *	2020-12-22	2021-07-30	吉林省特医食品生物科技有限公司	一种减轻体重的发酵型小分子肽及其制备方法和应用
WO2022156798A1 (zh) *	2021-01-25	2022-07-28	成都康弘生物科技有限公司	一种抗体及其用途
US20250325718A1 (en) *	2021-01-27	2025-10-23	Janssen Biotech, Inc.	Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
KR20230137410A (ko) *	2021-01-28	2023-10-04	아스트리아 테라퓨틱스, 인크.	혈장 칼리크레인 항체 및 이의 용도
CA3219934A1 (en)	2021-05-27	2022-12-01	Rhys Salter	Compositions and methods for the treatment of prostate cancer
JP2024542168A (ja)	2021-11-09	2024-11-13	ヤンセンバイオテツク，インコーポレーテツド	大員環化合物及びその製造方法
JP2024543046A (ja)	2021-11-09	2024-11-19	ヤンセンバイオテツク，インコーポレーテツド	大環状化合物及びその診断上の使用
CA3247163A1 (en)	2022-01-26	2023-08-03	Janssen Biotech, Inc.	Immunoconjugates comprising kallikrein-bound peptide-2 antigen-binding domains and their uses
WO2025244971A1 (en)	2024-05-20	2025-11-27	Janssen Biotech, Inc.	Compositions and methods for the treatment of prostate cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
SE459005B (sv)	1985-07-12	1989-05-29	Aake Rikard Lindahl	Saett att framstaella sfaeriska polymerpartiklar
US5807978A (en)	1995-06-07	1998-09-15	Kokolus; William J.	Immunogenic peptides of prostate specific antigen
US6379669B1 (en)	1995-08-04	2002-04-30	Akhouri A. Sinha	Targeting of organs by immunoconjugates
CA2192782C (en)	1995-12-15	2008-10-14	Nobuyuki Takechi	Production of microspheres
WO1998021365A2 (en)	1996-11-14	1998-05-22	Mayo Foundation For Medical Education And Research	Method for detection of metastatic prostate cancer
US7053042B1 (en)	1999-07-29	2006-05-30	Samuel Denmeade	Activation of peptide prodrugs by hK2
EP1206277A1 (en)	1999-08-16	2002-05-22	Zonagen, Inc.	Methods and materials for the treatment of prostatic carcinoma
FI20002127A0 (fi)	2000-09-27	2000-09-27	Artic Partners Oy Ab	Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
WO2002098897A2 (en)	2001-06-01	2002-12-12	Cornell Research Foundation, Inc.	Modified antibodies to prostate-specific membrane antigen and uses thereof
US7514078B2 (en) *	2001-06-01	2009-04-07	Cornell Research Foundation, Inc.	Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
AU2002362447A1 (en) *	2001-10-03	2003-04-14	University Of Rochester	Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
KR100708398B1 (ko)	2002-03-22	2007-04-18	(주) 에이프로젠	인간화 항체 및 이의 제조방법
JP2007525416A (ja)	2003-01-31	2007-09-06	アルボアバイオロジクス，インコーポレイテッド	早期活性化分子のターゲティングに基づく免疫調節
EP1610818A4 (en) *	2004-03-03	2007-09-19	Millennium Pharm Inc	MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF
CN101094869A (zh) *	2004-08-03	2007-12-26	戴埃克斯有限公司	Hk1结合蛋白
US7462697B2 (en)	2004-11-08	2008-12-09	Epitomics, Inc.	Methods for antibody engineering
US8663600B2 (en) *	2005-02-17	2014-03-04	Diaprost Ab	Diagnosis of prostate cancer
WO2006089231A2 (en) *	2005-02-18	2006-08-24	Medarex, Inc.	Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
CL2007002225A1 (es)	2006-08-03	2008-04-18	Astrazeneca Ab	Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
JP5398538B2 (ja)	2006-12-01	2014-01-29	メダレックス・リミテッド・ライアビリティ・カンパニー	Ｃｄ２２に結合するヒト抗体およびその使用
ES2560868T3 (es) *	2006-12-22	2016-02-23	Phadia Ab	Alérgeno de calicreína de próstata novedoso
US20100261620A1 (en)	2008-10-14	2010-10-14	Juan Carlos Almagro	Methods of Humanizing and Affinity-Maturing Antibodies
PL2771037T3 (pl) *	2011-10-28	2017-06-30	Fredax Ab	Środki terapeutyczne i ich zastosowania
AU2014351611B2 (en) *	2013-11-19	2020-04-23	Janssen Biotech, Inc.	Humanised anti kallikrein-2 antibody
WO2023278463A1 (en)	2021-06-29	2023-01-05	Volastra Therapeutics, Inc.	Anti-enpp1 antibodies and uses thereof

2014
- 2014-11-19 AU AU2014351611A patent/AU2014351611B2/en active Active
- 2014-11-19 IL IL311788A patent/IL311788B1/en unknown
- 2014-11-19 SI SI201431143T patent/SI3071595T1/sl unknown
- 2014-11-19 HR HRP20191095TT patent/HRP20191095T1/hr unknown
- 2014-11-19 RU RU2016124229A patent/RU2687163C1/ru active
- 2014-11-19 LT LTEP14814696.2T patent/LT3071595T/lt unknown
- 2014-11-19 CA CA2930493A patent/CA2930493A1/en active Pending
- 2014-11-19 HU HUE14814696A patent/HUE043875T2/hu unknown
- 2014-11-19 KR KR1020227003223A patent/KR102574537B1/ko active Active
- 2014-11-19 EP EP14814696.2A patent/EP3071595B1/en active Active
- 2014-11-19 MX MX2016006561A patent/MX383543B/es unknown
- 2014-11-19 SM SM20190338T patent/SMT201900338T1/it unknown
- 2014-11-19 BR BR112016011025-0A patent/BR112016011025B1/pt active IP Right Grant
- 2014-11-19 PL PL14814696T patent/PL3071595T3/pl unknown
- 2014-11-19 CN CN202011566401.5A patent/CN112898431B/zh active Active
- 2014-11-19 US US15/036,170 patent/US10100125B2/en active Active
- 2014-11-19 DK DK14814696.2T patent/DK3071595T3/da active
- 2014-11-19 KR KR1020167016169A patent/KR102442738B1/ko active Active
- 2014-11-19 KR KR1020237029468A patent/KR102894975B1/ko active Active
- 2014-11-19 PT PT14814696T patent/PT3071595T/pt unknown
- 2014-11-19 JP JP2016532031A patent/JP6599859B2/ja active Active
- 2014-11-19 IL IL297678A patent/IL297678B2/en unknown
- 2014-11-19 ES ES14814696T patent/ES2728515T3/es active Active
- 2014-11-19 RS RS20190729A patent/RS58831B1/sr unknown
- 2014-11-19 EP EP19161698.6A patent/EP3553088A1/en active Pending
- 2014-11-19 WO PCT/GB2014/053420 patent/WO2015075445A1/en not_active Ceased
- 2014-11-19 CN CN201480072422.8A patent/CN105980404B/zh active Active
2016
- 2016-05-11 IL IL245617A patent/IL245617B/en active IP Right Grant
- 2016-05-19 MX MX2021007006A patent/MX2021007006A/es unknown
2018
- 2018-08-30 US US16/117,522 patent/US11230609B2/en active Active
2019
- 2019-06-20 CY CY20191100645T patent/CY1121900T1/el unknown
- 2019-10-02 JP JP2019181801A patent/JP7051777B2/ja active Active
2020
- 2020-07-20 AU AU2020207775A patent/AU2020207775B2/en active Active
- 2020-11-04 IL IL278493A patent/IL278493B2/en unknown
2021
- 2021-09-16 US US17/476,683 patent/US12404343B2/en active Active
2022
- 2022-01-13 JP JP2022003634A patent/JP7592654B2/ja active Active
2023
- 2023-08-30 AU AU2023222879A patent/AU2023222879A1/en active Pending
2024
- 2024-11-19 JP JP2024201463A patent/JP2025019101A/ja active Pending
2025
- 2025-09-28 IL IL323633A patent/IL323633A/en unknown

Also Published As

Publication number	Publication date
IL278493B2 (en)	2023-04-01
LT3071595T (lt)	2019-05-10
AU2014351611A1 (en)	2016-06-30
KR102574537B1 (ko)	2023-09-06
KR20230132599A (ko)	2023-09-15
EP3553088A1 (en)	2019-10-16
KR102894975B1 (ko)	2025-12-04
HRP20191095T1 (hr)	2019-09-20
AU2023222879A1 (en)	2023-09-14
CA2930493A1 (en)	2015-05-28
US11230609B2 (en)	2022-01-25
IL297678B1 (en)	2024-05-01
KR20220020406A (ko)	2022-02-18
CN105980404A (zh)	2016-09-28
CN112898431B (zh)	2024-05-28
IL297678A (en)	2022-12-01
KR20160096621A (ko)	2016-08-16
MX383543B (es)	2025-03-14
IL323633A (en)	2025-11-01
JP2016540503A (ja)	2016-12-28
WO2015075445A1 (en)	2015-05-28
IL245617A0 (en)	2016-06-30
US12404343B2 (en)	2025-09-02
BR112016011025A2 (pt)	2017-12-05
AU2020207775A1 (en)	2020-08-06
JP2025019101A (ja)	2025-02-06
IL297678B2 (en)	2024-09-01
PT3071595T (pt)	2019-06-11
MX2016006561A (es)	2016-12-12
RS58831B1 (sr)	2019-07-31
AU2014351611B2 (en)	2020-04-23
ES2728515T3 (es)	2019-10-25
US10100125B2 (en)	2018-10-16
EP3071595B1 (en)	2019-03-20
HUE043875T2 (hu)	2019-09-30
JP7051777B2 (ja)	2022-04-11
CN105980404B (zh)	2021-01-12
RU2687163C1 (ru)	2019-05-07
SI3071595T1 (sl)	2019-08-30
CY1121900T1 (el)	2020-10-14
JP6599859B2 (ja)	2019-10-30
RU2016124229A (ru)	2017-12-25
US20160369009A1 (en)	2016-12-22
EP3071595A1 (en)	2016-09-28
AU2020207775B2 (en)	2023-06-15
JP2020022470A (ja)	2020-02-13
JP7592654B2 (ja)	2024-12-02
BR112016011025B1 (pt)	2024-01-23
IL311788A (en)	2024-05-01
JP2022062048A (ja)	2022-04-19
IL245617B (en)	2021-02-28
IL278493A (en)	2022-12-01
KR102442738B1 (ko)	2022-09-15
PL3071595T3 (pl)	2019-09-30
IL311788B1 (en)	2025-11-01
MX2021007006A (es)	2021-09-08
US20220064333A1 (en)	2022-03-03
SMT201900338T1 (it)	2019-07-11
US20190169312A1 (en)	2019-06-06
BR112016011025A8 (pt)	2018-01-30
CN112898431A (zh)	2021-06-04

Publication	Publication Date	Title
IL281485B (en)	2022-02-01	Tracked all-terrain vehicle
CY2023021I1 (el)	2024-02-16	Αντισωματα που δεσμευουν την il-23
DK3071595T3 (da)	2019-07-01	Humaniseret anti-kallikrein-2-antistof
DK3336106T3 (da)	2020-07-13	Anti-fcrh5-antistoffer
DK3708583T3 (da)	2022-05-16	Ikke-fucosylerede anti-fgfr2iiib-antistoffer
IL246287B (en)	2021-01-31	Fabs-in-tandem immunoglobulin and uses thereof
ME03675B (me)	2020-10-20	Humanizovana ili himerna anтi-cd3 antiтela
LT3049441T (lt)	2020-02-10	Anti-pdl1 antikūnų kompozicija
EP3083682C0 (en)	2024-04-17	DOUBLE SPECIFICITY ANTIBODIES
PT3088419T (pt)	2019-01-11	Conjugado de anticorpo anti-trop2-fármaco
BR112014024769A2 (pt)	2017-12-12	anticorpo humanizado tau
DK3083694T3 (da)	2024-01-29	Caniniserede, murine anti-canin-pd-1-antistoffer
IL243311A0 (en)	2016-03-31	Novel antibody frameworks
IL239688A0 (en)	2015-08-31	Antibodies comprising chimeric constant domains
EP3070168C0 (en)	2024-07-31	ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED ANTIBODY VARIABLE REGION
KR20180085002A (ko)	2018-07-25	인간화된 항-cll-1 항체
DK3068800T3 (da)	2019-10-21	FcRn-specifikke antistoffer
PL3088421T3 (pl)	2019-08-30	Przeciwciała monoklonalne do zastosowania w diagnostyce i leczeniu nowotworów i choroby autoimmunologicznej
DK3038643T3 (da)	2019-06-24	Antistoffer mod csf-1r
IL240753B (en)	2021-01-31	Methods for purifying antibodies
ME03094B (me)	2019-01-20	Protutijela protiv kemokina pan-elr+ схс
GB201300706D0 (en)	2013-02-27	Antibody
DK3065774T3 (da)	2021-08-23	Anti-CCL17-antistoffer
HRP20190085T1 (hr)	2019-03-08	Anti-cd52 protutijela
DK3047163T3 (da)	2020-03-02	Lukkeelement